SAB Biotherapeutics uses the DiversitAb platform to produce fully human polyclonal antibodies in genetically engineered transchromosomic cattle, removing the need for human donors. These antibodies are designed to treat immunology disorders and infectious diseases and include programs like SAB-142 for Type 1 Diabetes, SAB-176 for severe influenza, and SAB-195 for C. difficile infection. The platform can shorten development timelines, aiming to move candidates from concept to clinic in under five months, and it focuses on polyclonal antibodies rather than monoclonal ones. The company pursues regulatory approval and commercialization through collaborations with government agencies, academia, and pharmaceutical partners to address high-need diseases and biodefense applications.
Company Size
51-200
Company Stage
IPO
Headquarters
Miami Beach, Florida
Founded
2014
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?